Pro 2014-017 (Jianfeng Group Disposal of Assets Announcement)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2014-017
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Disposal of Assets by Subsidiaries
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Content Note:
l Brief Content: The Jiangnan Pharmaceutical Factory of Zhejiang Jianfeng Pharmaceutical Co., Ltd., a controlling subsidiary of the Company, located at 1756 Binhong Road, Xiguan Village, Jinhua Development Zone, is to be demolished. Recently, the Jinhua Economic and Technological Development Zone Management Committee and Zhejiang Jianfeng Pharmaceutical Co., Ltd. signed an Agreement to expropriate the land and other assets of Jianfeng Pharmaceutical Jiangnan Pharmaceutical Factory, and compensate for the expropriated land and real estate. The total compensation is 95.9167 million yuan (RMB).
l This matter does not constitute a related party transaction
l This matter does not constitute a major asset reorganization
l There are no major legal obstacles to the implementation of this matter
l According to the provisions of the Company's Articles of Association, this matter needs to be submitted to the Board of Directors of the Company for consideration, but does not need to the shareholders' meeting for consideration.
1. Overview
(I) In view of the fact that Jinhua municipal government has carried out renovation and demolition of enterprises in Jinhua Jiangnan Development Zone in order to speed up economic transformation and urban transformation. The company's holding subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical") is located at No. 1756 Binhong Road, Xiguan Village, Jinhua Development Zone, and the Jiangnan Pharmaceutical Factory is planned to be demolished. June 2014 30 , Jinhua Economic and Technological Development Zone Management Committee (hereinafter referred to as "Jinhua Economic Management Committee") and Zhejiang Jianfeng Pharmaceutical Co., Ltd. signed the Agreement. Jinhua Economic Management Committee will purchase and store 37016.3 ㎡ of land from Jiangnan Pharmaceutical Factory of Jianfeng Pharmaceutical Co., Ltd. and compensate and reward the expropriated land, real estate and other assets. The total amount of compensation and reward is 95.9167 million yuan (RMB).
(II) Board of Directors Review
The company held the 17th meeting of the 8th board of directors by correspondence on June 30, 2014. All eight directors of the company participated in the voting, the board of directors passed the "Proposal on Demolition of Jianfeng Pharmaceutical Jiangnan Pharmaceutical Factory" with 8 votes in favor, 0 votes against and 0 abstentions.
(III) According to the Articles of Association of the Company, the disposal of the asset is not required to be submitted to the General Meeting of Shareholders for consideration.
2. The main bodies of both parties
The main bodies of both parties in this asset disposal are the Management Committee of Jinhua Economic and Technological Development Zone and Zhejiang Jianfeng Pharmaceutical Co., Ltd., a holding subsidiary of the Company.
3. Disposal of Assets
(I) Basic Information
Involving this demolition is the overall assets such as houses, equipment and land use rights of Jianfeng Pharmaceutical Jiangnan Pharmaceutical Factory. The property rights of this part of the assets are clear, there are no mortgages, pledges or any other restrictions on transfer, no judicial matters such as seizure, freezing, litigation or arbitration, and no other circumstances that hinder the transfer of assets.
Jianfeng Pharmaceutical Jiangnan Pharmaceutical Factory is the main production base of Jianfeng Pharmaceutical's solid preparations. It was transformed on the basis of the acquisition of Jinhua Monosodium glutamate Factory in 1994. There are existing production lines and supporting facilities for tablets, dripping pills, freeze-dried powder injections, cephalosporin aseptic sub-packaging powder injections, bulk drugs, etc. Among them, the production lines for tablets and dripping pills are in normal production, freeze-dried powder injection, cephalosporin aseptic powder injection, raw materials and other production lines in Jinxi base for off-site transformation.
(II) Asset Evaluation
. For this asset transfer, Kunyuan Asset Evaluation Co., Ltd., which is qualified to engage in securities and futures business, was hired to conduct asset evaluation and issued "Asset Evaluation Report " (Kunyuan Evaluation Report [2014] No. 221). The base date of the assessment is April 30, 2014. For assets such as houses, pipelines and non-removable equipment, the replacement cost method is mainly used to determine their assessed value ; for non-removable trees, according to their specific varieties, specifications and other major parameters, the current market price is used as the compensation value; for removable equipment, according to the current relevant market price standards, the compensation value is based on the reasonable relocation expenses required for its protective demolition in the original factory area and its relocation to the new factory area to resume normal use. As for the land use right, Jinhua Huacheng Real Estate Land Evaluation Co., Ltd. entrusted Jinhua Huacheng Real Estate Land Evaluation Co., Ltd. to evaluate the land use right and issued "Land Evaluation Report ". This appraisal is based on the value of the land use rights contained in the appraisal report as its demolition compensation value. The evaluation results are listed below:
Project |
Net Book Value (Yuan) |
Appraisal Value (Yuan) |
Value Added (Yuan) |
Value Added Ratio (yuan) |
1. Housing Compensation Value |
10455370.00 |
21273590.00 |
10818220.00 |
103.47% |
2. Structures compensation Value |
2741175.40 |
3907960.00 |
1166784.60 |
42.57% |
3. Pipeline and Other Concealed Works Compensation Value |
1016483.53 |
847130.00 |
-169353.53 |
-16.66 |
4. Seedling Greening Compensation Value |
1354860.00 |
1354860.00 |
||
5. non-removable equipment compensation value |
3632714.15 |
3862560.00 |
229845.85 |
6.33% |
6. Removable Equipment Compensation Value |
1936160.00 |
|||
7. Land Compensation Value |
4678895.40 |
37756626.00 |
33077730.60 |
706.96% |
Total |
22524638.48 |
70938886.00 |
46478087.52 |
206.34% |
this evaluation, the value-added of the house appraisal was 103.47 per cent and the value-added of the land appraisal was 706.96 per cent, mainly due to the fact that the land of the plant was acquired earlier and the cost of building the house was lower. In addition, the assessed value of the compensation value of the removable equipment is based on the reasonable relocation costs required for the protective demolition of the part of the equipment and the relocation to the new plant area to return to normal use, not the replacement value of the part of the equipment.
2. This asset transfer is based on the "Asset Appraisal Report" issued by Kunyuan Asset Appraisal Co., Ltd., and the compensation and incentives for the demolished assets are determined through negotiation between the two parties. The main contents of the
4. agreement
"Jinhua Economic Management Committee" or "Party A": Jinhua Economic and Technological Development Zone Management Committee
"Jianfeng Pharmaceutical" or "Party B": Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Party A and Party B intend to sign an agreement in the near future. The main contents of the agreement are as follows:
(I) Party B agrees that Party A shall purchase and store the land located at Jiangnan Pharmaceutical Factory, No. 1756 Binhong Road, Xiguan Village, Jinhua Development Zone, with the land use certificate No. 6-3344 of Jinshi Guoyong (2003) Zi. The land is industrial land with a land area of 37016.3 ㎡.
(II) Party A to compensate and reward the above-mentioned land, real estate, equipment and appendages expropriated by Party B, according to the evaluation report issued by Kunyuan Asset Evaluation Co., Ltd. (Kunyuan Evaluation Report [20 14 ] 221 </
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page